ArticleMolecular cancer research : MCR2019
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Breast cancer ovarian metastases show increased activity of GPCR pathways.bioRxiv : the preprint server for biology · 2026Article
- Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.Endocrinology · 2024Review
- EstroGene database reveals diverse temporal, context-dependent and directional estrogen receptor regulomes in breast cancer.bioRxiv : the preprint server for biology · 2023Article
- ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).PLoS genetics · 2023Article
- Molecular characterization of ESR1 variants in breast cancer.Breast cancer research and treatment · 2022Article
- Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective.International journal of molecular sciences · 2021Review
- Article
- Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview.Endocrine-related cancer · 2021Review
- Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.Breast cancer research : BCR · 2021Review
- Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences.Breast cancer research : BCR · 2021Article
- Network Pharmacology Integrated with Molecular Docking Explores the Mechanisms of Naringin against Osteoporotic Fracture by Regulating Oxidative Stress.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Currently Applied Molecular Assays for IdentifyingInternational journal of molecular sciences · 2020Review
- Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma.Endocrinology · 2020Article
- Robust and accurate deconvolution of tumor populations uncovers evolutionary mechanisms of breast cancer metastasis.Bioinformatics (Oxford, England) · 2020Article
- Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.Medical sciences (Basel, Switzerland) · 2020Review
- Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors.Journal for immunotherapy of cancer · 2019Article
- Identification of key pathways and genes in colorectal cancer to predict the prognosis based on mRNA interaction network.Oncology letters · 2019Article
- Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.Cancer letters · 2019Article
- Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.Journal of translational medicine · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 4 countries.
Ahmed BasudanDepartment of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-6689-7004
Nolan PriedigkeitWomen's Cancer Research Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Ryan J HartmaierWomen's Cancer Research Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Ethan S SokolFoundation Medicine, Cambridge, Massachusetts.
Amir BahreiniWomen's Cancer Research Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Rebecca J WattersDepartment of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0001-7486-7510
Michelle M BoisenWomen's Cancer Research Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Rohit BhargavaWomen's Cancer Research Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Kurt R WeissDepartment of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Maria M KarstenCharité-Universitätsmedizin Berlin, Berlin, Germany.
Carsten DenkertCharité-Universitätsmedizin Berlin, Berlin, Germany.
Jens-Uwe BlohmerCharité-Universitätsmedizin Berlin, Berlin, Germany.
Jose P LeoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Ronald L HamiltonDepartment of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-6802-1102
Adam M BrufskyWomen's Cancer Research Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Esther ElishaevWomen's Cancer Research Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Peter C LucasDepartment of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Adrian V LeeDepartment of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0001-9917-514X
Steffi OesterreichWomen's Cancer Research Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania. oesterreichs@upmc.edu.ORCID 0000-0002-2537-6923
University of Pittsburgh · USCharité - Universitätsmedizin Berlin · DEDana-Farber Cancer Institute · USGlobalFoundries (United States) · USIsfahan University of Medical Sciences · IRUPMC Hillman Cancer Center · US
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD · 1988 to 2026
$158.0MPREDOCTORAL TRAINING IN PHARMACOLOGICAL SCIENCEST32GM008424 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PAGANO, PATRICK J · 1994 to 2019
$3.4MExploring Sarcoma Metastatic PotentialK08CA177927 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WEISS, KURT RICHARD · 2013 to 2017
$827kTranscriptomic profiling and functional characterization of fusion genes in recurrent ovarian cancerF30CA203095 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PRIEDIGKEIT, NOLAN · 2016 to 2018
$135kNCI NIH HHS F30 CA203095NCI NIH HHS K08 CA177927NCI NIH HHS P30 CA047904NIGMS NIH HHS T32 GM008424
Abstract
DNA sequencing has identified a limited number of driver mutations in metastatic breast cancer beyond single base-pair mutations in the estrogen receptor (
Indexed as
Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase Inhibitor ProteinsDNA Copy Number VariationsDNA, NeoplasmEstrogen Receptor alphaFemaleGene AmplificationHumansMCF-7 CellsNeoplasm MetastasisRNA, MessengerSignal TransductionCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Cyclin-Dependent Kinase Inhibitor ProteinsDNA, NeoplasmESR1 protein, humanEstrogen Receptor alphaRNA, Messenger
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.